Navigation Links
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
Date:3/3/2009

Studies Support Potential for Alzheimer's Disease and Other Neurodegenerative Diseases

NEW YORK, March 3 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that the chemical structure of OXIGON(TM) (indole-3-propionic acid) has been independently shown to form copper complexes. This discovery provides important insight into how the drug neutralizes the neurotoxicity of Alzheimer's beta-amyloid toxin, previously reported by several investigators. Also, it provides further support that OXIGON(TM) has broad potential for use in the treatment of other neurodegenerative conditions, such as Parkinson's disease, where metal binding is believed to induce the pathological aggregation of proteins. The discovery regarding the metal binding properties of OXIGON(TM) was reported by Professor Liang Hong and colleagues from Guangxi Normal University, Guilin, China, in February 2008 in an online publication, CJI.

Intellect is developing OXIGON(TM) as a drug candidate for AD. The drug, which has disease-modifying potential by preventing metal-dependent aggregation, neurotoxicity and deposition of beta amyloid, has been tested in human Phase I trials for safety and tolerability at various doses and different durations in a total of 90 elderly, healthy volunteers. The development of OXIGON(TM) as a drug candidate for AD has been supported in part by the National Institute of Aging, the BIRD Foundation and The Institute for the Study of Aging. The Company is seeking additional investments to support initiation of Phase II clinical trials for OXIGON(TM) in Alzheimer's patients.

Dr. Daniel Chain, Intellect's Chairman and CEO commented: "We were very interested to learn that OXIGON(TM) has metal binding properties." Dr. Chain added: "These data fit perf
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
2. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
3. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
4. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
5. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
9. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
10. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
11. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Researchers from the North American Menopause Society (NAMS) found ... too high, 1 putting women at risk for ... close to menopause are commonly told to take supplements ... as osteoporosis, to which they are particularly prone. ... calcium they typically get through their food sources before ...
(Date:7/23/2014)... 2014 This September leading clinicians in orthodontics ... Vegas for DOCtalk 2014 —a "Dynamic ... thinker and private practitioner Dr. David Sarver , ... discuss clinical and practice management efficiency and high quality ... opportunity to welcome fresh thinking and join a community ...
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... a pharmaceutical company dedicated to improving healthcare through ... range of prescription and over-the-counter ("OTC") products, today ... Mr. Tony Liu and Chief Financial Officer, Ms. ...
... that a new market research report is available in ... in China http://www.reportlinker.com/p0363587/The-Top-10-CMOs-in-China.html ... and future outlook of CMO industry in China. It ... the top 10 CMOs. Other leading players are also ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds The Top 10 CMOs in China 2
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... Adipic acid is an intermediate chemical ... plastic, often referred to as engineering thermoplastics. These ... the monomers employed. Due to the high production ... increasing number of developing countries, the Asia-Pacific region ... by Europe and North America. Adipic acid in ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Children and teens who lose ... death in adulthood, a new study suggests. People who ... 50 percent greater risk of death during the study period ... parent, according to the report. Although the study found ... risk of premature death, it wasn,t designed to prove cause-and-effect. ...
(Date:7/23/2014)... ill patients arriving at the emergency department, the ... amnesia for rapid, life-saving intubation, despite decades-old studies ... results of a systematic review of 10 recent ... a "wonder drug" are published online in ... of Ketamine on Intracranial and Cerebral Perfusion Pressure ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... Bulgaria is to ban the imports of live birds, eggs ... reported suspected bird flu outbreaks. The first case of bird ... province near the Aegean Sea in Western Turkey. Following the ... being slaughtered in order to prevent the spread of the ...
... new study has linked beta-carotene to heart diseases. The ... of deaths in elderly with heart diseases. ,The ... significant after considering other risk factors, according to the ... previous studies that either suggest the carotenoid raises the ...
... novel initiative to combat the spread of childhood obesity, ... of the William J. Clinton Foundation and the American ... a partnership with Nickelodeon's award-winning Let's Just Play pro-social ... a comprehensive media and public awareness campaign, encouraging young ...
... nutritionally good compounds. Lot of research is being done ... herbs, fruits, and vegetables, slowed the growth of prostate ... ,Previous studies already found flavonoids (found in fruits and ... of cancers. ,The current study was intended to ...
... its major 29 hospitals to share information about its ... and interlinking of data would be helpful to citizen ... the case history and treatment provided to this patient. ... with different hospital departments. From a patient's personal information ...
... linked to a number of psychiatric disorders, including ... Early smoking is shown to increase the risk ... disorder, generalized anxiety disorder), and that presence of ... risk for later development of nicotine dependence. ...
Cached Medicine News:Health News:A New Initiative To Fight Childhood Obesity 2Health News:Prostate tumour growth suppressed by flavonoids 2Health News:Delhi Government To Interlink All Major Hospitals Through e-Governance 2Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2
... injectable low osmolar, nonionic, contrast media ... biologically inert when injected intra-arterially. Each ... of ioversol, 3.6 mg of tromethamine ... of edetate calcium disodium as a ...
... is a non-ionic monomeric contrast medium for ... and children. After a decade of clinical ... examinations, IMAGOPAQUE has proven to be a ... hundreds of radiology departments.Results from large multicentre ...
... ProHance® (gadoteridol) is a contrast medium ... form of a sterile, apyrogenic solution for ... contrast enhancement of the brain, spine and ... with unenhanced MRI) of lesions with abnormal ...
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
Medicine Products: